/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE
SERVICES OR FOR DISSEMINATION IN THE
UNITED STATES./
TORONTO, Sept. 20, 2018 /CNW/ - 48North Cannabis Corp.
("48North" or the "Company") (TSXV:NRTH) is
announcing the completion of Phase I of its project to bring its
top performing cannabis cultivars to the Canadian market. Following
the importation of 6,650 cannabis seeds from Netherlands-based MariPharm B.V., the Company
embarked on a project to select and cultivate its most promising
phenotypes at the Company's wholly-owned licensed facility, DelShen
Therapeutics Corp. ("DelShen") located in Kirkland Lake, Ontario.
Phase I cultivars:
- Girl Scout Cookies
- Granddaddy Purple
- Green Crack
- Kosher Kush
- Power Plant
- High CBD
"The DelShen production team has been working hard over the past
year to cultivate top cannabis strains and we are happy with the
results our first round of testing has shown," said Kevin Helfand, Chief Operating Officer at
48North. "We are seeing high yields for certain cultivars and we
now have multiple high tetrahydrocannabinol ("THC") strains
being grown. As the legalization of adult recreational cannabis
approaches, we are fulfilling our commitment to grow unique
genetics of the highest quality to suit our future customers'
varying demands."
Completing this project has allowed the DelShen grow team to
analyze its genetic library, use expert data analytics, and select
phenotypes with a wide range of cannabinoids and terpenes that are
underrepresented in the current Canadian market.
Phase II of the phenotype selection project will be to re-test
the new cultivars after some additional flowering time to optimize
both yields and resin profiles. "Our lab results indicate
sufficient cannabigerolic acid to anticipate higher resin
profiles," continued Mr. Helfand. "We believe the Green Crack, a
sativa dominant hybrid, can consistently express over 25 percent
THC content and the Kosher Kush can yield over 200 grams of dried
cannabis per plant with some additional data analysis. Once this
phase is completed, we will decide which cultivars to put into
full-scale production, as well as commence Phase III, the phenotype
selection of the other cultivars we have in our genetic library,
including Amnesia, Gorilla Glue #4 and Super Silver Haze."
About 48North
48North Cannabis Corp.
("48North") is a TSX Venture Exchange listed company whose
wholly owned subsidiary DelShen Therapeutics Corp.
("DelShen"), is a licensed producer of medical cannabis in
Canada. 48North grows unique
genetics sourced from MariPharm B.V., a Netherlands-based phytopharmaceutical company
with over 25 years of experience in the research and cultivation of
cannabis for medical purposes. Its genetics are grown to exacting
standards, ensuring patients can count on receiving the
highest-quality cannabis products.
DelShen is regulated by the Access to Cannabis for Medical
Purposes Regulations and the facility is located on
800-acres of owned land near Kirkland
Lake, Ontario. DelShen's license to produce cannabis
was granted on February 28, 2017, its
cannabis sales license was granted on June
25, 2018, and its extraction license to produce cannabis
oils was granted on September 13,
2018, and pertain to the facility, a state-of-the-art,
closed-box, 40,000-square-foot building.
DISCLAIMER & READER ADVISORY
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accept responsibility for the adequacy or
accuracy of this release.
Certain statements contained in this press release constitute
forward-looking information. These statements relate to future
events or future performance. The use of any of the words "could",
"intend", "expect", "believe", "will", "projected", "estimated" and
similar expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking
information and are based on the parties' current belief or
assumptions as to the outcome and timing of such future events.
Actual future results may differ materially. The business of the
Company is subject to a number of material risks and uncertainties.
Please refer to the Filing Statement and other SEDAR filings for
further details. Various assumptions or factors are typically
applied in drawing conclusions or making the forecasts or
projections set out in forward-looking information. Those
assumptions and factors are based on information currently
available to the parties. The material factors and assumptions
include the Company being able to obtain the necessary corporate,
regulatory and other third parties approvals, and licensing and
other risks associated with regulated ACMPR entities. The forward
looking information contained in this release is made as of the
date hereof and the parties are not obligated to update or revise
any forward looking information, whether as a result of new
information, future events or otherwise, except as required by
applicable securities laws. Because of the risks, uncertainties and
assumptions contained herein, investors should not place undue
reliance on forward looking information. The foregoing statements
expressly qualify any forward-looking information contained
herein.
SOURCE 48North Cannabis Corp.